Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

To assess the pharmacodynamics (PD) of biomarkers amyloid beta peptide 40 and 42 (Ab40 and Ab42) in CSF, following single oral doses of GSI-953, an investigational drug, in healthy young subjects and patients with Alzheimer Disease (AD).

Key facts

Study ID

NCT00479219

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

17

Starts

2007-05-01

Expected to finish

2007-10-01

Last updated by the study team

2008-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• For Healthy Young Subjects: Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and 12 lead ECGs.
• For AD patients: Patients must be generally healthy with the exception of Alzheimer Disease. (same as above)

Where it is running

• Study site — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.